Amgen Inc. AMGN
414.61
8.57
2.11%
as of 25 Sep
- Market cap
- $219.1B
- P/E
- 25.6×
Follow AMGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Amgen Inc. (AMGN) Revenue growth
Amgen Inc.'s revenue growth over the twelve months to 30 June 2026 was 9.10%, down 0.9 percentage points from fiscal 2025 (9.95%). Over the past ten years it has ranged from −1.62% (fiscal 2019) to 18.6% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Drug Manufacturers General industry median of 6.79% and above the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 9.95% | (8.62) |
| FY2024 | 18.6% | 11.48 |
| FY2023 | 7.09% | 5.77 |
| FY2022 | 1.32% | (0.86) |
| FY2021 | 2.18% | (6.65) |
| FY2020 | 8.83% | 10.45 |
| FY2019 | −1.62% | (5.55) |
| FY2018 | 3.93% | 4.55 |
| FY2017 | −0.62% | (6.76) |
| FY2016 | 6.14% | (1.83) |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 9.53% | 3.77 |
| Mar 2026 | 5.76% | (2.82) |
| Dec 2025 | 8.58% | (3.82) |
| Sep 2025 | 12.4% | 2.97 |
| 42 more quarters | Free account |
Against its own ten years
Low −1.62%
High 18.6%
Ten-year median
6.14%
Current reading's percentile
91
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NVO Novo Nordisk A/S compare | 13.2% |
| ABBV AbbVie Inc. compare | 10.4% |
| AMGN Amgen Inc. | 9.10% |
| AZN AstraZeneca PLC compare | 8.61% |
| GILD Gilead Sciences, Inc. compare | 5.52% |
| MRK Merck & Co., Inc. compare | 4.64% |
| BMY Bristol Myers Squibb Company compare | 3.11% |
| NVS Novartis AG compare | 2.73% |
| PFE Pfizer Inc. compare | −0.21% |
| Drug Manufacturers General industry median | 6.79% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on AMGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement